{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:41:45Z","timestamp":1792662105860,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40119-026-00470-8","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:50:29Z","timestamp":1787838629000},"page":"19-36","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular-Related Mortality and Hospitalizations in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: A Post Hoc Analysis of the Phase\u00a03 ATTR-ACT and Long-Term Extension"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct01994889","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02791230","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4058-3848","authenticated-orcid":false,"given":"Thibaud","family":"Damy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3043-1472","authenticated-orcid":false,"given":"Ronald","family":"Witteles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1622-0732","authenticated-orcid":false,"given":"Francesco","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2541-4440","authenticated-orcid":false,"given":"Martha","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"470_CR1","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:2872\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2019.04.003.","journal-title":"J Am Coll Cardiol"},{"key":"470_CR2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.amjcard.2021.02.035","volume":"148","author":"AB Miller","year":"2021","unstructured":"Miller AB, Januzzi JL, O\u2019Neill BJ, et al. Causes of cardiovascular hospitalization and death in patients with transthyretin amyloid cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]). Am J Cardiol. 2021;148:146\u201350. https:\/\/doi.org\/10.1016\/j.amjcard.2021.02.035.","journal-title":"Am J Cardiol"},{"key":"470_CR3","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1002\/ejhf.3540","volume":"27","author":"L Zeldin","year":"2025","unstructured":"Zeldin L, Eichler JBS, Teruya SL, et al. Outpatient worsening of heart failure and mortality in transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2025;27:2661\u2013970. https:\/\/doi.org\/10.1002\/ejhf.3540.","journal-title":"Eur J Heart Fail"},{"key":"470_CR4","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1002\/ehf2.13913","volume":"9","author":"R Lauppe","year":"2022","unstructured":"Lauppe R, Liseth Hansen J, Fornwall A, et al. Healthcare resource use of patients with transthyretin amyloid cardiomyopathy. ESC Heart Fail. 2022;9:1636\u201342. https:\/\/doi.org\/10.1002\/ehf2.13913.","journal-title":"ESC Heart Fail"},{"key":"470_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02425-3","volume":"17","author":"SC Jang","year":"2022","unstructured":"Jang SC, Nam JH, Lee SA, et al. Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis. Orphanet J Rare Dis. 2022;17:262. https:\/\/doi.org\/10.1186\/s13023-022-02425-3.","journal-title":"Orphanet J Rare Dis"},{"key":"470_CR6","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.amjcard.2019.08.045","volume":"124","author":"BW Sperry","year":"2019","unstructured":"Sperry BW, Saeed IM, Raza S, Kennedy KF, Hanna M, Spertus JA. Increasing rate of hospital admissions in patients with amyloidosis (from the National Inpatient Sample). Am J Cardiol. 2019;124:1765\u20139. https:\/\/doi.org\/10.1016\/j.amjcard.2019.08.045.","journal-title":"Am J Cardiol"},{"key":"470_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.102766","volume":"14","author":"P Garc\u00eda-Pav\u00eda","year":"2026","unstructured":"Garc\u00eda-Pav\u00eda P, Witteles RM, Damy T, et al. Monitoring disease progression in patients with transthyretin amyloid cardiomyopathy: a JACC: Heart Failure Position Statement. JACC Heart Fail. 2026;14:102766. https:\/\/doi.org\/10.1016\/j.jchf.2025.102766.","journal-title":"JACC Heart Fail"},{"key":"470_CR8","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1805689.","journal-title":"N Engl J Med"},{"key":"470_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ejhf.2027","volume":"23","author":"T Damy","year":"2021","unstructured":"Damy T, Garcia-Pavia P, Hanna M, et al. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021;23:277\u201385. https:\/\/doi.org\/10.1002\/ejhf.2027.","journal-title":"Eur J Heart Fail"},{"key":"470_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","volume":"15","author":"P Elliott","year":"2022","unstructured":"Elliott P, Drachman BM, Gottlieb SS, et al. Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ Heart Fail. 2022;15:e008193. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.008193.","journal-title":"Circ Heart Fail"},{"key":"470_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.102122","volume":"4","author":"MG Crespo-Leiro","year":"2025","unstructured":"Crespo-Leiro MG, Hanna M, Damy T, et al. Early access to tafamidis for patients with transthyretin amyloid cardiomyopathy. JACC Adv. 2025;4:102122. https:\/\/doi.org\/10.1016\/j.jacadv.2025.102122.","journal-title":"JACC Adv"},{"key":"470_CR12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1159\/000525883","volume":"147","author":"H Li","year":"2022","unstructured":"Li H, Rozenbaum M, Casey M, Sultan MB. Estimating the effect of tafamidis on cardiovascular-related hospitalization in NYHA class\u00a0III patients with transthyretin amyloid cardiomyopathy in the presence of death. Cardiology. 2022;147:398\u2013405. https:\/\/doi.org\/10.1159\/000525883.","journal-title":"Cardiology"},{"key":"470_CR13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40256-021-00464-y","volume":"21","author":"C Vong","year":"2021","unstructured":"Vong C, Boucher M, Riley S, Harnisch LO. Modeling of survival and frequency of cardiovascular-related hospitalization in patients with transthyretin amyloid cardiomyopathy treated with tafamidis. Am J Cardiovasc Drugs. 2021;21:535\u201343. https:\/\/doi.org\/10.1007\/s40256-021-00464-y.","journal-title":"Am J Cardiovasc Drugs"},{"key":"470_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003815","author":"MS Maurer","year":"2017","unstructured":"Maurer MS, Elliott P, Merlini G, et al. Design and rationale of the phase\u00a03 ATTR-ACT clinical trial (tafamidis in transthyretin cardiomyopathy clinical trial). Circ Heart Fail. 2017. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.116.003815.","journal-title":"Circ Heart Fail"},{"key":"470_CR15","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/cpdd.789","volume":"9","author":"PA Lockwood","year":"2020","unstructured":"Lockwood PA, Le VH, O\u2019Gorman MT, et al. The bioequivalence of tafamidis 61-mg free acid capsules and tafamidis meglumine 4 x 20-mg capsules in healthy volunteers. Clin Pharmacol Drug Dev. 2020;9:849\u201354. https:\/\/doi.org\/10.1002\/cpdd.789.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"470_CR16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s40256-022-00526-9","volume":"22","author":"MH Rozenbaum","year":"2022","unstructured":"Rozenbaum MH, Tran D, Bhambri R, Nativi-Nicolau J. Annual cardiovascular-related hospitalization days avoided with tafamidis in patients with transthyretin amyloid cardiomyopathy. Am J Cardiovasc Drugs. 2022;22:445\u201350. https:\/\/doi.org\/10.1007\/s40256-022-00526-9.","journal-title":"Am J Cardiovasc Drugs"},{"key":"470_CR17","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ejhf.2198","volume":"23","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Bengel F, Brito D, et al. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2021;23:895\u2013905. https:\/\/doi.org\/10.1002\/ejhf.2198.","journal-title":"Eur J Heart Fail"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00470-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-026-00470-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00470-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:15:33Z","timestamp":1792660533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-026-00470-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":17,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["470"],"URL":"https:\/\/doi.org\/10.1007\/s40119-026-00470-8","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Thibaud Damy reports speaking fees, research grants, or consulting fees from Pfizer, Bridgebio, Ionis Pharmaceuticals, AKCEA, AstraZeneca, NovoNordisk, Alnylam Pharmaceuticals, and Alexion. Ronald Witteles served as a paid adviser to Alexion, Alnylam, AstraZeneca, Bridge Bio, Intellia, Medison, Novo Nordisk, and Pfizer. Francesco Cappelli has acted as a consultant, advisor, or speaker for Alnylam Pharmaceuticals, Bayer, AstraZeneca, BridgeBio (formerly Eidos Therapeutics), Novo Nordisk, and Pfizer. Ronnie Wang is an employee of and owns stock\/options in Pfizer. Martha Grogan reports research funding from Alnylam, Eidos, Pfizer, Novo Nordisk, and Janssen; license\/patent pending from Anumana (algorithm to detect cardiac amyloidosis using AI ECG); Advisory Boards for Janssen, Novo Nordisk, Alnylam, BridgeBio, and AstraZeneca.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"These studies were approved by the independent review board or ethics committee at each participating center and was conducted in accordance with the concepts laid out in the Declaration of Helsinki of 1964, its later amendments, and the International Conference on Harmonization Good Clinical Practice guidelines. All patients provided written informed consent.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}